Sagimet Biosciences Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs, private third-party payors, Medicare, Medicaid, and the Children’s Health Insurance Program. Recipients of payments or transfers of value from manufacturers include physicians—such as doctors, dentists, optometrists, podiatrists, and chiropractors—other healthcare professionals like physician assistants and nurse practitioners, and teaching hospitals. The markets served encompass pharmaceutical manufacturers and wholesale distributors required to comply with state laws concerning registration, product tracking, marketing compliance, and reporting related to sales, marketing, pricing, and interactions with healthcare providers.
Sagimet Biosciences has announced the publication of pivotal results from its Phase 2b FASCINATE-2 clinical trial investigating denifanstat, a novel therapeutic agent targeting biopsy-confirmed F2/F3 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH). The results, published in The Lancet Gastroenterology and Hepatology , illustrate the drug’s potential in not only improving disease activity but also achieving significant resolution of MASH and reduction in fibrosis.The FASCINATE-2 trial evaluated the efficacy and safety of denifanstat in patients diagnosed with moderate to severe MASH, a condition characterized by fat accumulation in the liver that can lead to severe complications, including ...
Sagimet Biosciences Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs, private third-party payors, Medicare, Medicaid, and the Children’s Health Insurance Program. Recipients of payments or transfers of value from manufacturers include physicians—such as doctors, dentists, optometrists, podiatrists, and chiropractors—other healthcare professionals like physician assistants and nurse practitioners, and teaching hospitals. The markets served encompass pharmaceutical manufacturers and wholesale distributors required to comply with state laws concerning registration, product tracking, marketing compliance, and reporting related to sales, marketing, pricing, and interactions with healthcare providers.
Sources:
Sagimet Biosciences inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Sagimet Biosciences inc’s corporate clients.
For your research, we’ve provided 9 tables on Sagimet Biosciences inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
